Abstract
5q-associated spinal muscular atrophy (SMA) is a rare genetic disease caused by mutations in the SMN1 gene, resulting in a loss of functional SMN protein and consecutive degeneration of motor neurons in the ventral horn. The disease is clinically characterized by proximal paralysis and secondary skeletal muscle atrophy. New disease-modifying drugs driving SMN gene expression have been developed in the past decade and have revolutionized SMA treatment. The rise of treatment options led to a concomitant need of biomarkers for therapeutic guidance and an improved disease monitoring. Intensive efforts have been undertaken to develop suitable markers, and numerous candidate biomarkers for diagnostic, prognostic, and predictive values have been identified. The most promising markers include appliance-based measures such as electrophysiological and imaging-based indices as well as molecular markers including SMN-related proteins and markers of neurodegeneration and skeletal muscle integrity. However, none of the proposed biomarkers have been validated for the clinical routine yet. In this narrative review, we discuss the most promising candidate biomarkers for SMA and expand the discussion by addressing the largely unfolded potential of muscle integrity markers, especially in the context of upcoming muscle-targeting therapies. While the discussed candidate biomarkers hold potential as either diagnostic (e.g., SMN-related biomarkers), prognostic (e.g., markers of neurodegeneration, imaging-based markers), predictive (e.g., electrophysiological markers) or response markers (e.g., muscle integrity markers), no single measure seems to be suitable to cover all biomarker categories. Hence, a combination of different biomarkers and clinical assessments appears to be the most expedient solution at the time.
Introduction
The landscape of 5q-associated spinal muscular atrophy (SMA) has been transformed by recent disease-modifying therapies, shifting the focus from palliative care to precision monitoring. SMA is a rare genetic disorder caused by a deficiency in the Survival Motor Neuron (SMN) protein, leading to the progressive death of motor neurons and severe muscle wasting. The last decade has seen a "therapeutic revolution" with the approval of gene therapies (onasemnogene abeparvovec) and splice modulators (nusinersen, risdiplam). While these drugs are life-changing, they introduce a new challenge: therapeutic guidance. Clinicians need objective ways to determine which patients will respond best to which drug, when to switch therapies, and how to monitor "silent" disease progression.
Categorizing the Biomarker Landscape
To systematically evaluate candidate biomarkers, researchers utilize the FDA’s BEST (Biomarkers, EndpointS, and other Tools) resource. This framework categorizes markers based on their clinical utility, ranging from diagnostic and prognostic to predictive and response-monitoring roles.
A Multimodal Approach to Monitoring
This review argues that no single "magic bullet" biomarker exists; instead, clinicians must adopt a multimodal approach—combining molecular, electrophysiological, and imaging data—to effectively guide treatment and predict patient outcomes. The authors synthesize findings to categorize candidate markers across four primary domains: molecular analytes, physiological measures, imaging, and digital assessments.
Key Candidate Biomarkers
Molecular Markers
- SMN Protein: Shows high potential as a response marker, particularly for systemic treatments like risdiplam.
- Neurofilaments (pNFH/NFL): Validated as strong prognostic and response markers in pediatric populations. Their utility in adults is currently less clear, likely due to a smaller pool of degenerating neurons or a more stabilized disease state.
- Creatinine (Crn): A simple blood-derived marker that correlates with muscle mass. It has shown high potential for predicting and monitoring treatment response across age groups.
Physiological and Digital Markers
- Electrophysiology (CMAP/MUNE): These remain the "gold standard" for monitoring the functional status of motor units, showing clear improvements in children following gene therapy.
- Digital Biomarkers: Tools like the Konectom app or ActiMyo sensors allow for continuous monitoring of upper limb function in real-world settings, capturing fluctuations that annual clinical visits might miss.
The "Muscle Turn"
While SMA is primarily a motor neuron disease, there is untapped potential in muscle integrity markers. As new therapies begin to target skeletal muscle directly (e.g., myostatin inhibitors), markers like Creatinine and Creatine Kinase (CK) are becoming vital for monitoring peripheral response.
Conclusion and Future Directions
The primary limitation is a lack of clinical validation. While many markers show "high potential," none have been officially qualified for routine clinical decision-making. Future research must focus on longitudinal data for adult cohorts, standardization of imaging techniques like quantitative MRI (qMRI), and the development of standardized "biomarker cocktails" that provide a holistic view of patient health.
Summary updated